No material news briefings with verified dates were included in the provided context for this reporting period. The report is therefore based on SEC filings, institutional ownership disclosures, and macro data available as of the generation date of 11 September 2026.
Eli Lilly's trailing twelve-month revenue to 30 June 2026 stood at $79.67 billion, representing year-over-year growth of 47.7% [SEC 10-Q - LLY - 2026-06-30]. Net income over the same period was $26.71 billion, producing a net margin of 33.5% [SEC 10-Q - LLY - 2026-06-30]. Earnings per share grew 26.2% year-over-year, and the price-to-earnings ratio was recorded at 37.68 [SEC 10-Q - LLY - 2026-06-30]. The company held $8.95 billion in cash against total debt of $54.91 billion as of 30 June 2026 [SEC 10-Q - LLY - 2026-06-30].
Insider activity in the 30 days to September 2026 comprised seven transactions with a net selling direction, totalling a net disposal value of approximately $7.64 million [SEC Form 4 - LLY - 2026-09]. On the institutional side, several notable position changes were recorded in the most recent 13F filings. Citadel added 46% to its LLY position, AQR Capital added 21%, and Bridgewater added 23% [SEC 13F - Citadel - Q2 2026; SEC 13F - AQR Capital - Q2 2026; SEC 13F - Bridgewater - Q2 2026]. ARK Invest increased its position by 509%, while Millennium reduced its holding by 14% [SEC 13F - ARK Invest - Q2 2026; SEC 13F - Millennium - Q2 2026]. These institutional movements represent the primary trigger for this report.
The prevailing macro environment as of the generation date shows the 10-year US Treasury yield at 4.83% and the 2-year yield at 4.39%, producing a normal yield curve spread of 44 basis points [FRED DGS10; FRED DGS2]. The elevated rate environment remains a factor in the broader cost of capital context for large-capitalisation pharmaceutical issuers carrying substantial debt loads.